Evidence map›Paper›PMID 33688647›Full record

ArticlebioRxiv : the preprint server for biology2021

Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters.

Neil C Dalvie, Sergio A Rodriguez-Aponte, Brittany L Hartwell, Lisa H Tostanoski, Andrew M Biedermann, Laura E Crowell, Kawaljit Kaur, Ozan Kumru, Lauren Carter, Jingyou Yu and 30 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 19 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

40 authors at 8 institutions in 1 country.

Neil C DalvieDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Sergio A Rodriguez-AponteThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Brittany L HartwellThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Lisa H TostanoskiCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Andrew M BiedermannDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Laura E CrowellDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Kawaljit KaurDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, Kansas, 66047, United States.
Ozan KumruDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, Kansas, 66047, United States.
Lauren CarterDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Jingyou YuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Aiquan ChangCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Katherine McMahanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Thomas CourantVaccine Formulation Institute, 1228 Plan-Les-Ouates, Geneva, Switzerland.
Celia LebasVaccine Formulation Institute, 1228 Plan-Les-Ouates, Geneva, Switzerland.
Ashley A LemniosThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Kristen A RodriguesThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Murillo SilvaThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Ryan S JohnstonThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Christopher A NaranjoThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Mary Kate TraceyThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Joseph R BradyDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Charles A WhittakerThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Dongsoo YunThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Swagata KarBioqual, Inc., Rockville, MD 20850, USA.
Maciel PortoBioqual, Inc., Rockville, MD 20850, USA.
Megan LokBioqual, Inc., Rockville, MD 20850, USA.
Hanne AndersenBioqual, Inc., Rockville, MD 20850, USA.
Mark G LewisBioqual, Inc., Rockville, MD 20850, USA.
Kerry R LoveDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Danielle L CampThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Judith Maxwell SilvermanBill & Melinda Gates Medical Research Institute, Cambridge, MA 02139, USA.
Harry KleanthousBill&Melinda Gates Foundation, Seattle, WA 98109, USA.
Sangeeta B JoshiDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, Kansas, 66047, United States.
David B VolkinDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, Kansas, 66047, United States.
Patrice M DuboisVaccine Formulation Institute, 1228 Plan-Les-Ouates, Geneva, Switzerland.
Nicolas CollinVaccine Formulation Institute, 1228 Plan-Les-Ouates, Geneva, Switzerland.
Neil P KingDepartment of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Dan H BarouchRagon Institute of MGH, MIT, Harvard, Cambridge, MA 02139, USA.
Darrell J IrvineThe Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
J Christopher LoveDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Massachusetts Institute of Technology · USBeth Israel Deaconess Medical Center · USBioqual · USUniversity of Kansas · USGates Foundation · USRagon Institute of MGH, MIT and Harvard · USUniversity of Washington · USHoward Hughes Medical Institute · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond · 1985 to 2026
$93.9M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
NCI NIH HHS P30 CA014051NIAID NIH HHS T32 AI007387
6 · The paper itself

Abstract

Global containment of COVID-19 still requires accessible and affordable vaccines for low- and middle-income countries (LMICs).

Identifiers

PMID33688647
PMCPMC7941618
OpenAlexW3135063017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.